For all forms of TB, outcome definitions have many similarities. These are:
- Outcome assignment is standardized, as to permit comparisons across clinicians, time and sites.
- Outcome assignment relies heavily, but not exclusively, on bacteriologic endpoints (smear or culture a Citation a. Molecular techniques are not used to monitor treatment response or to declare failure. These tests may identify dead bacilli for a long time and can even be positive after a patient is truly cured. ).
- Outcomes are mutually exclusive and exhaustive.
For all forms of TB, definitions exist for:
- Interim outcomes (intended to have an indication on how the programme is functioning before final outcomes are available);
- Final outcomes (cure, completion, failure, treatment interruption, death or not evaluated).
17.2.1 Interim outcomes for drug-susceptible TB and MDR-TB
Given that TB treatment is long (6 to 18 months or more), interim outcomes provide early indicators of programme results. Table 17.1 provides a summary on interim outcomes.
TB |
Interim outcomes |
---|---|
Drug-susceptible TB |
At 2-3 and 4-5 months:
|
MDR-TB |
At 6 months:
|
17.2.2 Final outcomes for drug-susceptible TB and DR-TB
Table 17.2 provides definitions for the final outcomes.
Table 17.2 - Summary table of final outcome definitions
[1]
Citation
1.
Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2005:9(6):640–5.
[2]
Citation
2.
World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision (WHO/HTM/TB/2013.2). WHO Geneva. 2013.
http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
Outcomes |
TB |
Definitions |
---|---|---|
Cured |
DS TB |
Patient initially bacteriologically confirmed (microscopy, culture or molecular test) who completed treatment |
PDR-TB |
Patient initially bacteriologically confirmed (culture or molecular test), who completed treatment |
|
MDR-TB |
Patient initially bacteriologically confirmed (culture or molecular test), who completed treatment If there is a lone positive culture or smear reported during that time, and no concomitant clinical evidence of deterioration, a patient may still be considered cured, provided that this positive culture is followed by a minimum of 3 consecutive negative cultures taken at least 30 days apart. |
|
Completed |
All |
Patient who completed treatment |
Failure
|
DS TB |
Patient with signs of continued active disease or deterioration requiring a treatment change: |
DR-TB (a) Citation a. A patient registered as “failure” can be re-registered as DR-TB “previously treated 2nd line” and started again on a new regimen if possible. (b) Citation b. This category does not include the changing of one drug due to an adverse effect or a temporary cessation of drugs in order to manage severe adverse event. (c) Citation c. If a patient was defined as a “failure”, and no appropriate treatment was possible, but the treatment was continued and the patient subsequently interrupted the treatment or died, the outcome is “failure” (the first outcome is recorded).
|
Treatment terminated or need for permanent treatment change of at least 2 classes of anti-TB drugs because of one or more of the following: |
|
Interrupted | All | Patient who interrupted treatment for 2 months or more. |
Death | All | Patient who died on TB treatment or while awaiting TB treatment, irrespective of the cause of death. The cause of death should be recorded. |
Treatment adapted (d) Citation d. For programmes that report using the WHO’s mutually exclusive six outcomes, the “treatment adapted” outcome can be added to failures for reporting purposes, but should also be kept track of separately for good programmatic monitoring and evaluation. (e) Citation e. Not applicable for DR-TB. |
DS TB | Patient initially treated with a standard regimen and for whom the treatment is secondarily adapted according to the results of DST (and not because of a treatment failure). |
Not evaluated | All | Patient whose treatment outcome is unknown (including patients “transferred out” to another treatment centre, for whom the outcome is unknown). |
If treatment is continuing at the time of a cohort analysis, an outcome of “still on treatment” may be provisionally assigned
- (a)Molecular techniques are not used to monitor treatment response or to declare failure. These tests may identify dead bacilli for a long time and can even be positive after a patient is truly cured.
- (a)A patient registered as “failure” can be re-registered as DR-TB “previously treated 2nd line” and started again on a new regimen if possible.
- (b)This category does not include the changing of one drug due to an adverse effect or a temporary cessation of drugs in order to manage severe adverse event.
- (c)If a patient was defined as a “failure”, and no appropriate treatment was possible, but the treatment was continued and the patient subsequently interrupted the treatment or died, the outcome is “failure” (the first outcome is recorded).
- (d)For programmes that report using the WHO’s mutually exclusive six outcomes, the “treatment adapted” outcome can be added to failures for reporting purposes, but should also be kept track of separately for good programmatic monitoring and evaluation.
- (e)Not applicable for DR-TB.
- 1.Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2005:9(6):640–5.
- 2.World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision (WHO/HTM/TB/2013.2). WHO Geneva. 2013.
http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf